OMERS Administration Corp purchased 50,671 shares of Axsome Therapeutics, Inc. The new position is valued at approximately $12.4 million according to a recent SEC filing. This investment provides OMERS with a 0.10% stake in the biotechnology firm. Other institutional investors and hedge funds are also currently adjusting their Axsome holdings.
H.C. Wainwright reiterated a buy rating on Axsome stock with a $290 price target. The rating follows a second-quarter earnings report where Auvelity sales exceeded consensus estimates. Guggenheim and Needham also recently raised their price targets for the company. Analysts cited robust sales performance and an expanded sales force as primary growth drivers.